Silence Therapeutics (Silence Therapeutics) Additional Paid-In Capital : $324.86 Mil(As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Silence Therapeutics Additional Paid-In Capital?

Silence Therapeutics's quarterly additional paid-in capital increased from Jun. 2023 ($296.75 Mil) to Sep. 2023 ($305.47 Mil) and increased from Sep. 2023 ($305.47 Mil) to Dec. 2023 ($324.86 Mil).

Silence Therapeutics's annual additional paid-in capital increased from Dec. 2021 ($252.03 Mil) to Dec. 2022 ($282.42 Mil) and increased from Dec. 2022 ($282.42 Mil) to Dec. 2023 ($324.86 Mil).

Silence Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Silence Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silence Therapeutics Additional Paid-In Capital Chart

Silence Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

187.87

213.61

252.03

282.42

324.86

Silence Therapeutics Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															282.42	281.45	296.75	305.47	324.86

Silence Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Silence Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Silence Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Silence Therapeutics (Silence Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silence Therapeutics PLC (NAS:SLN) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

SLNCF:USA XRP2:Germany

Address

72 Hammersmith Road, London, GBR, W14 8TH

Website

https://www.silence-therapeutics.com

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risk of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.